Hologic
30-Second Executive Brief
Executive Assessment
Hologic functions as a regional institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, though its relative influence is cooling.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A women's health diagnostics and medical technology company that was taken private in April 2026 through a Blackstone- and TPG-led acquisition valued at up to $79 per share, with José (Joe) E. Almeida appointed CEO effective at close. Hologic's fiscal Q1 2026 revenue reached $1,047.8 million (up 2.5%), and the company presented new data at ASCO 2026 showing its Breast Cancer Index test meaningfully shifts physician recommendations on extended endocrine therapy for HR-positive early-stage breast cancer patients.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Hologic — Blackstone and TPG complete acquisition of Hologiccompany
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Hologic — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Hologic's take-private trades external transparency for potential longer-horizon strategic latitude
29% confidenceBlackstone and TPG completed their take-private acquisition of Hologic in April 2026 for up to $79 per share, installing a new CEO, which means the women's health diagnostics leader will report far less frequently and in less detail than it did as a public company.
This is InsightNodes' own interpretive read: private-equity ownership typically allows management to pursue multi-year operational or R&D investments without the quarterly earnings pressure public markets impose, which can be genuinely useful for a diagnostics company validating tests like the Breast Cancer Index over long clinical timelines -- but it also means external observers, including competitors and partners, lose the visibility into performance trends that public filings previously provided, making it harder to independently verify how the business is actually performing post-acquisition.
InsightNodes analysis of Hologic's ownership transition · Aug 14, 2026
Hologic's Timeline
A sourced, dated history of Hologic's key moments — founding to present.
Apr 2026 · Taken private by Blackstone and TPG
Blackstone and TPG completed their acquisition of Hologic in a transaction valued at up to $79 per share, with José (Joe) E. Almeida appointed CEO effective immediately upon close.
May 2026 · Presents Breast Cancer Index data at ASCO 2026
Hologic presented new data at ASCO 2026 showing its Breast Cancer Index test meaningfully influences physician decisions on extended endocrine therapy for HR-positive early-stage breast cancer.